N. M. Lindor, S. N. Thibodeau, and W. Burke, Whole-genome sequencing in healthy people, Mayo Clin Proc, vol.92, pp.159-72, 2017.

M. Plöthner, M. Frank, V. Der-schulenburg, and J. G. , Cost analysis of whole genome sequencing in German clinical practice, Eur J Health Econ, vol.18, pp.623-656, 2017.

K. J. Van-nimwegen, R. A. Van-soest, J. A. Veltman, M. R. Nelen, G. J. Van-der-wilt et al., Is the $1000 genome as near as we think? A cost analysis of next-generation sequencing

, Clin Chem, vol.62, issue.11, pp.1458-64, 2016.

M. A. Hamburg and F. S. Collins, The path to personalized medicine, N Engl J Med, vol.363, pp.301-305, 2010.

C. Truntzer, D. Maucort-boulch, and P. Roy, Comparative optimism in models involving both classical clinical and gene expression information, BMC Bioinformatics, vol.9, p.434, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00428280

J. P. Ioannidis, Why most published research findings are false, PLoS Med, vol.2, p.124, 2005.

S. M. Lee, M. Falzon, F. Blackhall, J. Spicer, M. Nicolson et al., Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 Trial (ET), J Clin Oncol, vol.35, pp.402-413, 2017.

J. De-leon, Evidence-based medicine versus personalized medicine: are they enemies?, J Clin Psychopharmacol, vol.32, pp.153-64, 2012.

S. S. Kalia, K. Adelman, S. J. Bale, W. K. Chung, C. Eng et al., Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics, Genet Med, vol.19, pp.249-55, 2017.

M. Inouye, G. Abraham, C. P. Nelson, A. M. Wood, M. J. Sweeting et al., Genomic risk prediction of coronary artery disease in 480,000 adults: Implications for primary prevention, J Am Coll Cardiol, vol.72, pp.1883-93, 2018.

N. Picard, J. C. Boyer, E. Mc, B. Guellec, C. Thomas et al., Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx), Therapie, vol.72, pp.175-83, 2017.

C. H. Van-der-wouden, A. Cambon-thomsen, E. Cecchin, K. C. Cheung, and C. L. Dávila-fajardo,

V. H. Deneer, Implementing pharmacogenomics in Europe: design and implementation strategy of the Ubiquitous Pharmacogenomics Consortium, Clin Pharmacol Ther, vol.101, pp.341-58, 2017.

F. Gueyffier, P. Piedbois, J. F. Bergmann, B. Avouac, T. Borel et al., Comment mesure-t-on le bénéfice net d'un traitement ?, Therapie, vol.72, pp.51-61, 2017.

G. Chatellier, V. Varlet, C. Blachier-poisson, N. Beslay, J. M. Behier et al., Big data" and "open data": What kind of access should researchers enjoy?, 2016.

, , vol.71, pp.107-121

, Contribution du Comité consultatif national d'éthique à la révision de la loi de bioéthique, 2018.

P. Marino, R. Touzani, L. Perrier, E. Rouleau, D. S. Kossi et al., Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study, Eur J Hum Genet, vol.26, pp.314-337, 2018.
URL : https://hal.archives-ouvertes.fr/halshs-01703194

K. Schwarze, J. Buchanan, J. C. Taylor, and S. Wordsworth, Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature, Genet Med, vol.20, pp.1122-1152, 2018.

C. S. Bennette, C. J. Gallego, W. Burke, G. P. Jarvik, and D. L. Veenstra, The cost-effectiveness of returning incidental findings from next-generation genomic sequencing, Genet Med, vol.17, pp.587-95, 2015.

K. Payne, S. P. Gavan, S. J. Wright, and A. J. Thompson, Cost-effectiveness analyses of genetic and genomic diagnostic tests, Nat Rev Genet, vol.19, pp.235-281, 2018.

O. Rejeb, C. Pilet, S. Hamana, X. Xie, T. Durand et al., Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation, Health Care Manag Sci, vol.21, pp.204-227, 2018.
URL : https://hal.archives-ouvertes.fr/halshs-01526704

, Haute autorité de santé. Guide méthodologique. Choix méthodologique pour l'évaluation économique à la HAS. Octobre, 2011.

P. Tuppin, J. Rudant, P. Constantinou, C. Gastaldi-ménager, A. Rachas et al., Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national